Results 181 to 189 of about 12,098 (189)

Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma

JCO Precision Oncology, 2020
Christopher D, Jakubowski, Aditya A, Mohan, Ihab R, Kamel, Mark, Yarchoan   +3 more
openaire   +2 more sources

MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

Journal of Thoracic Oncology, 2022
Fan, Y., Drilon, Alexander Edward, Chiu, Chao-Hua, Bowles, D.W., Loong, H.H.F., Siena, Salvatore, Goto, K., Krzakowski, M., Ahn, M.-J, Murakami, H., Dziadziuszko, Rafal, Zeuner, H., Pitcher, B., Cheick, D., Krebs, Matthew   +14 more
openaire   +1 more source

Personalisierte Therapie des ROS1- Fusions-positiven NSCLC

Im Fokus Onkologie, 2020
openaire   +1 more source

Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

The Lancet Oncology, 2020
openaire   +3 more sources

Les protéines de fusion ROS1, cibles du foretinib

Bulletin du Cancer, 2014
openaire   +1 more source

Repotrectinib effective in ROS1-fusion-positive NSCLC

Nature Reviews Clinical Oncology
openaire   +2 more sources

EP.12.42 Durable Response to ROS1-Tkis in Metastatic Squamous NSCLC With EZR-ROS1 Fusion

Journal of Thoracic Oncology
E.M. Urbanska, E.S. Petersson, M.H. Suppli, M. Grauslund, J.B. Sørensen, E. Santoni-Rugiu   +5 more
openaire   +1 more source

NTRK-, ROS1 oder ALK-Fusions-positive Tumoren im Fokus

InFo Hämatologie + Onkologie, 2019
openaire   +1 more source

P3.12.04 Taletrectinib, a Next Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models

Journal of Thoracic Oncology
H. Patel, L. Heller, K. Bowman, Z. Hu, Y. Zhang, I.M. Grossi, M. Pan, G. Hattersley   +7 more
openaire   +1 more source